Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients

Plain-language summary

This study examines how genetic polymorphisms affect the response to beta blocker therapy in Egyptian patients. People aged 18-75 who are beta-blocker naive or who have been on beta-blocker therapy for at least 4 weeks could take part. It was a study without a phase designation and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Mohamed Saleh Fayed

Start date

5/5/2021

Estimated completion

8/1/2021

Countries

Egypt

Related genes

Locations

• Cairo, Egypt

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Beta-blockers naïve patients
2. Patients been on beta-blocker therapy for at least 4 weeks.
3. Age (18-75) Years old.

Exclusion Criteria:

1. Non-Egyptians.
2. Kidney failure of any stage.
3. Liver failure of any stage.
4. Malignancy.
5. Pregnancy.
6. HR \< 55 beats/min (in the absence of b-blocker therapy).
7. Presence of a cardiac pacemaker.